grant
5/5 Biomarkers to Enhance Early Schizophrenia Treatment (BEEST)
Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 5 Sept 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY202512-20 years oldAbilifyAccelerationAdherenceAdolescenceAgeAgranulocytosisAntipsychotic AgentsAntipsychotic DrugsAntipsychoticsBiological MarkersBrainBrain Nervous SystemBrain scanCaringClinicalClozapineComplexControlled StudyCorpus StriatumCorpus striatum structureCountryDataDecision MakingDedicationsDevelopmentDoseDrugsEducationEducational aspectsElementsEmploymentEncephalonFailureFamilyFamily memberFeeling suicidalFunctional MRIFunctional Magnetic Resonance ImagingFutureGeneral PopulationGeneral PublicGenotypeGoalsGranulocytopeniaHLA-DQB1HLA-DQB1 antigenHLA-DQbeta1Hospital AdmissionHospitalizationHospitalsImageIndividualLifelong disabilityLived experienceLived experiencesMC4 ReceptorMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMajor TranquilizersMajor Tranquilizing AgentsMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMelanocortin 4 ReceptorNIMHNMR ImagingNMR TomographyNational Institute of Mental HealthNeuroleptic AgentsNeuroleptic DrugsNeurolepticsNeutropeniaNuclear Magnetic Resonance ImagingOutcomePatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPatternPermanent disabilityPersonsPharmaceutical PreparationsPharmacogeneticsPhasePopulationPrecision therapeuticsPsychiatryPsychosesPsychotic DisordersPublishingRandomizedRandomized, Controlled TrialsReceptor GeneReceptor, Melanocortin, Type 4Research DesignResistanceRestRiskRisk-associated variantRisperidoneSchizophreniaSchizophrenic DisordersServicesStriate BodyStriatumStudy TypeSubgroupSuicidal thoughtsSymptomsSystemTestingTherapeuticWeightWeight GainWeight IncreaseWorkYouthYouth 10-21Zeugmatographyacute careadolescence (12-20)adult youthagedagesaripiprazolebio-markersbiologic markerbiomarkerblindbody weight gainbody weight increaseclinical validationcohortcostcritical developmental periodcritical perioddementia praecoxdetermine efficacydevelopmentaldisabilitydissemination strategydrug/agentearly adulthoodearly psychosisefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy trialemerging adultevaluate efficacyexamine efficacyexpectationexperiencefMRIfMRI scanfirst episode psychosisfunctional MRI scanfunctional magnetic resonance imaging scanfunctional outcomesgene locusgene testinggene-based testinggenetic locusgenetic testinggenomic locationgenomic locushigh riskimagingimplementation scienceimprovedimproved outcomeindexinginpatient careinpatient servicemortalitypatient oriented outcomesprecision therapiesprecision treatmentpredict responsivenesspredicting responsepredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreservationprimary outcomepsychoticpsychotic illnessrandomisationrandomizationrandomized control trialrandomized, clinical trialsrandomly assignedreduce suicidalityreduce suicidereducing suicidalityreducing suicideresistantresperidoneresponders and non-respondersresponders from non-respondersresponders or non-respondersresponders versus non-respondersresponders vs non-respondersresponders/nonrespondersresponseresponse to therapyresponse to treatmentrisk allelerisk generisk genotyperisk locirisk locusrisk variantschizophrenicsecondary outcomeside effectspecific biomarkersstriatalstudy designsuicidal ideationsuicidal morbiditysuicidal risksuicidal thinkingsuicide deathsuicide ideationsuicide morbiditysuicide risksupport toolstherapeutic responsetherapy responsethoughts about suicidetooltreatment responsetreatment responsivenesstrial comparingweightswt gainyoung adultyoung adult ageyoung adulthoodyouth age
Description preview
PROJECT SUMMARY
The onset of a first episode of psychosis (FEP) in late adolescence or early adulthood often leads to lifelong
disability. Timing and precision of treatment are of the essence during this critical developmental period.
Unfortunately, FEP patients who do not respond to a conventional first-line antipsychotic (FL-AP) are often…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click